NCT01120418View on ClinicalTrials.gov

Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

October 31, 2007

Study Completion Date

February 29, 2008

Conditions
Healthy
Interventions
DRUG

Besifloxacin Ophthalmic Suspension 0.6%

administered 3 times a day for 5 days to one eye.

Trial Locations (1)

14609

Bausch & Lomb, Rochester

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY

NCT01120418 - Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days | Biotech Hunter | Biotech Hunter